Clover joins COVID-19 vaccine party with Chinese launch

14 February 2023

Chinese biotech Clover Biopharmaceuticals (HKEX: 02197) has launched its protein-based COVID-19 vaccine in China.

The first doses of the recombinant SARS-CoV-2 subunit vaccine have been delivered and administered in Changxing, Zhejiang, as part of the campaign for China’s second booster dose and fourth jab overall, targeting older adults, immuno-compromized people and those with comorbidities.

Joshua Liang, chief executive and executive director of Clover, said: “We are very proud to be delivering on our commitment to help protect the elderly and other vulnerable populations with our premium COVID-19 booster vaccine, and commencing the launch in Zhejiang province where our vaccine is manufactured.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK